Population Pharmacokinetic/Pharmacodynamic (PK/PD) Modeling of Depot Testosterone Cypionate in Healthy Male Subjects.

about

Population Pharmacokinetic/Pharmacodynamic (PK/PD) Modeling of Depot Testosterone Cypionate in Healthy Male Subjects.

Item

http://www.wikidata.org/entity/Q50045237

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

Population Pharmacokinetic/Pha ...... nate in Healthy Male Subjects.

@en

Population Pharmacokinetic/Pharmacodynamic

@nl

type

Item

label

Population Pharmacokinetic/Pha ...... nate in Healthy Male Subjects.

@en

Population Pharmacokinetic/Pharmacodynamic

@nl

prefLabel

Population Pharmacokinetic/Pha ...... nate in Healthy Male Subjects.

@en

Population Pharmacokinetic/Pharmacodynamic

@nl

P1476

Population Pharmacokinetic/Pha ...... nate in Healthy Male Subjects.

@en

P2093

Daryl J Murry

http://www.w3.org/2001/XMLSchema#string

Michael Ellerby

http://www.w3.org/2001/XMLSchema#string

Paul J Perry

http://www.w3.org/2001/XMLSchema#string

Youwei Bi

http://www.w3.org/2001/XMLSchema#string

P2860

Molecular basis of androgen insensitivity.

Intramuscular injection of testosterone undecanoate for the treatment of male hypogonadism: phase I studies.

TESTOSTERONE PRODUCTION RATES IN NORMAL ADULTS.

Effects of androgenic-anabolic steroids in athletes.

Effects of chronic testosterone administration in normal men: safety and efficacy of high dosage testosterone and parallel dose-dependent suppression of luteinizing hormone, follicle-stimulating hormone, and sperm production.

Use of doping agents, particularly anabolic steroids, in sports and society.

Flip-flop pharmacokinetics--delivering a reversal of disposition: challenges and opportunities during drug development

Current concepts in anabolic-androgenic steroids.

Population pharmacokinetic/pharmacodynamic (PK/PD) modelling of the hypothalamic-pituitary-gonadal axis following treatment with GnRH analogues.

P304

259-268

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/PSP4.12287

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2018-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29436172

http://www.w3.org/2001/XMLSchema#string

P932

5915615

http://www.w3.org/2001/XMLSchema#string